TheraCryf held its AGM yesterday at which management emphasised its focus on brain disorders and specifically on advancing the Orexin (Ox-1) programme acquired in the Chronos transaction to clinical stage readiness by the end of calendar 2026, for which the company is now fully funded. The legacy synthetic Sulforaphane molecule (SFX-01) continues to be progressed in third-party funded programmes, most notably in the potential treatment for the brain cancer Glioblastoma at the Erasmus Medical Center in Rotterdam. The most important point in the AGM presentation on progress was that the Ox-1 programme is on time and on plan but there was useful incremental detail on both Ox-1 and SFX-01. TheraCryf continues to trade at a discounted valuation relative to peers, we believe given its potential for collaboration with big Pharma, milestone payments, and active clinical work with multiple inflection points of newsflow.
